Skip to main content
EXOSOME ATLAS

Product- and indication-specific assessment

Safety, product quality and consultation questions

Practical questions about product identity, route, regulatory status and cost.

Make “Is it safe?” specific

Safety depends on the product, source, production, route and individual. A topical study does not validate injection. No serious adverse events in a small group does not exclude rare or delayed effects.

Ask for the exact product name, manufacturer, lot information, storage requirements, proposed route and human evidence for that use. A single figure such as “billions of particles” does not measure clinical benefit.

Read regulatory status accurately

The FDA consumer information states that there are no FDA-approved exosome products in the United States. The source was checked on 22 September 2026. This is US information and does not by itself determine a particular product’s legal status in Türkiye.

In Türkiye, current official records and documentation must be assessed for the exact product and proposed use. A trial registration, manufacturer certificate or published paper is not by itself authorization for that product and procedure.

FDA consumer information (United States)

Assess cost alongside alternatives

A single “exosome price” often groups different preparations and procedures together. A written plan should state the preparation, accompanying procedure, rationale for sessions, follow-up and how to report problems. Fixed-session prescriptions or guaranteed outcomes deserve scrutiny against evidence.

This portal is educational and does not mean that every application discussed is offered at the clinic. Dr. Hamza Gemici’s clinic is in Ataşehir, Istanbul. A consultation should examine your goal, established options and the basis for any proposal together.

Sources for this guide

  1. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Welsh JA, Goberdhan DCI, O'Driscoll L et al. · J Extracell Vesicles · 2024. PMID 38326288.
  2. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. Park GH, Kwon HH, Seok J et al. · J Cosmet Dermatol · 2023. PMID 37377400.

Continue exploring

This selected-literature guide is neither a service menu nor a systematic review. It does not imply that every application discussed is offered at the clinic.

Publisher: Dr. Hamza Gemici clinic ·

Editorial policy